Cohen-Solal M - Search Results

1

Inadequate response to treatment reveals persistent osteoclast bone resorption in osteoporotic patients.

Léger B, Fardellone P, Cormier C, Ostertag A, Funck-Brentano T, Fabre S, Marty C, Jean-Luc B, Cohen-Solal M. Léger B, et al. Bone. 2021 Dec;153:116167. doi: 10.1016/j.bone.2021.116167. Epub 2021 Sep 4. Bone. 2021. PMID: 34492359

2

Non-aluminic adynamic bone disease in non-dialyzed uremic patients: a new type of osteopathy due to overtreatment?

Cohen-Solal ME, Sebert JL, Boudailliez B, Westeel PF, Morinière PH, Marie A, Garabedian M, Fournier A. Cohen-Solal ME, et al. Bone. 1992;13(1):1-5. doi: 10.1016/8756-3282(92)90354-y. Bone. 1992. PMID: 1581102

3

Relationship between the number of resorbing cells and the amount resorbed in metabolic bone disorders.

Cohen-Solal M, Morieux C, de Vernejoul MC. Cohen-Solal M, et al. J Bone Miner Res. 1991 Sep;6(9):915-20. doi: 10.1002/jbmr.5650060904. J Bone Miner Res. 1991. PMID: 1789139

4

Bone biopsy studies in the diagnosis and treatment of renal osteodystrophy.

Sebert JL, Fardellone P, Noel C, Cohen-Solal M, Bellony R, Marie A, Fournier A. Sebert JL, et al. Contrib Nephrol. 1988;64:49-57. doi: 10.1159/000415727. Contrib Nephrol. 1988. PMID: 3180824 No abstract available.

5

Short-term local injections of transforming growth factor-beta 1 decrease ovariectomy-stimulated osteoclastic resorption in vivo in rats.

Beaudreuil J, Mbalaviele G, Cohen-Solal M, Morieux C, De Vernejoul MC, Orcel P. Beaudreuil J, et al. J Bone Miner Res. 1995 Jun;10(6):971-7. doi: 10.1002/jbmr.5650100619. J Bone Miner Res. 1995. PMID: 7572322

6

Cytokine-mediated bone resorption in patients with the hyperimmunoglobulin E syndrome.

Cohen-Solal M, Prieur AM, Prin L, Denne MA, Launay JM, Graulet AM, Brazier M, Griscelli C, de Vernejoul MC. Cohen-Solal M, et al. Clin Immunol Immunopathol. 1995 Jul;76(1 Pt 1):75-81. doi: 10.1006/clin.1995.1090. Clin Immunol Immunopathol. 1995. PMID: 7606871

7

Bone resorption at the femoral neck is dependent on local factors in nonosteoporotic late postmenopausal women: an in vitro-in vivo study.

Cohen-Solal ME, Graulet AM, Gueris J, Denne MA, Bergot C, Morieux C, Sedel L, Kuntz D, De Vernejoul MC. Cohen-Solal ME, et al. J Bone Miner Res. 1995 Feb;10(2):307-14. doi: 10.1002/jbmr.5650100219. J Bone Miner Res. 1995. PMID: 7754812

8

Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma.

Roux C, Ravaud P, Cohen-Solal M, de Vernejoul MC, Guillemant S, Cherruau B, Delmas P, Dougados M, Amor B. Roux C, et al. Bone. 1994 Jan-Feb;15(1):41-9. doi: 10.1016/8756-3282(94)90890-7. Bone. 1994. PMID: 8024850

9

Histomorphometric effect of six month treatment with oral Risedronate in patients with multiple myeloma.

Cohen-Solal ME, Roux C, Valentin-Opran A, Dougados M, Amor B, De Vernejoul MC. Cohen-Solal ME, et al. Bone. 1993 May-Jun;14(3):505-9. doi: 10.1016/8756-3282(93)90187-f. Bone. 1993. PMID: 8363900 No abstract available.

10

Bone mass in middle-aged osteoporotic men and their relatives: familial effect.

Cohen-Solal ME, Baudoin C, Omouri M, Kuntz D, De Vernejoul MC. Cohen-Solal ME, et al. J Bone Miner Res. 1998 Dec;13(12):1909-14. doi: 10.1359/jbmr.1998.13.12.1909. J Bone Miner Res. 1998. PMID: 9844109 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

276 results

Search Page

Filters